Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. (NLTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NLTX · as of Jun 30, 2023
Ownership Breakdown
38
Institutional Holders
▲ 1 vs Q1
$14.44M
Total Inst. Value
▲ $3.90M vs Q1
2.35M
Shares Outstanding
freeFloat 58.03%
17.40M
13F Shares Held
▲ 2.34M vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NLTX largest shareholders · institutional ownership
Q2 2023 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP pharmaceutical preparations | 3.82M | 6.90% | 6.90% | $3.17B | Aug 14, 2023 | — held |
LYNX1 CAPITAL MANAGEMENT LP pharmaceutical preparations | 3.09M | 5.58% | 5.58% | $2.57B | Aug 14, 2023 | ▲ 666.2K |
REDMILE GROUP, LLC pharmaceutical preparations | 2.91M | 5.25% | 5.25% | $2.42B | Aug 14, 2023 | ▲ 1.06M |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 1.16M | 2.09% | 2.09% | $962.81M | Aug 14, 2023 | ▲ 3.2K |
VANGUARD GROUP INC pharmaceutical preparations | 1.01M | 1.82% | 1.82% | $838.97M | Aug 14, 2023 | ▼ 5.5K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 937.2K | 1.69% | 1.69% | $778.00M | Aug 11, 2023 | ▲ 22.6K |
WESTERN STANDARD LLC pharmaceutical preparations | 860.9K | 1.55% | 1.55% | $714.53M | Aug 14, 2023 | NEW |
MORGAN STANLEY pharmaceutical preparations | 822.0K | 1.48% | 1.48% | $682.24M | Aug 14, 2023 | ▲ 307 |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 609.7K | 1.10% | 1.10% | $506.01M | Aug 14, 2023 | ▼ 167.5K |
BLACKROCK INC. pharmaceutical preparations | 483.9K | 87.32% | 87.32% | $401.68M | Aug 11, 2023 | ▼ 80.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2023 vs prior quarter
Q2 2023
7
Increased
+1.76M shares7
New Positions
first time holders10
Decreased
−347.3K shares7
Sold Out
fully exitedNet shares change (top 50)
+1.41M
+1.76M / −347.3K
Net new holders
-3
7 new / 7 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NLTX insider trading · insider activity
Source: SEC Form 4
6
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Woods Robert Keith director | Jan 16, 2024 | Award | 15,400 | $32.30 | $497.4K | 15.4K | Form 4 ↗ |
PALEKAR ROHAN director | Jan 16, 2024 | Award | 15,400 | $32.30 | $497.4K | 15.4K | Form 4 ↗ |
Noonberg Sarah B. director | Jan 16, 2024 | Award | 15,400 | $32.30 | $497.4K | 15.4K | Form 4 ↗ |
Freedland Cory S. director | Jan 16, 2024 | Award | 15,400 | $32.30 | $497.4K | 15.4K | Form 4 ↗ |
BAFFI ROBERT director | Jan 16, 2024 | Award | 15,400 | $32.30 | $497.4K | 15.4K | Form 4 ↗ |
Jordan Julie Chief Medical Officer | Jan 16, 2024 | Award | 75,000 | $32.30 | $2.42M | 75.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Neoleukin Therapeutics, Inc. (NLTX) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 41.97%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Neoleukin Therapeutics, Inc. is BAKER BROS. ADVISORS LP, holding approximately 3.82 million shares — equal to 6.90% of outstanding shares — as of June 30, 2023.
A total of 38 institutional investors currently hold NLTX stock, with a combined institutional value of approximately $14,438,232 as of the most recent 13F filing period.
Frequently asked questions
NLTX ownershipNeoleukin Therapeutics, Inc. (NLTX) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BAKER BROS. ADVISORS LP with a 6.90% stake. Company insiders hold 41.97%. Data sourced from SEC Form 13F as of June 30, 2023.